Stewardship

The 2012 BIO International Convention featured a broad array of top-level speakers, addressing critical global challenges and the top issues in biotechnology. Hosted by the Biotechnology Industry Organization (BIO), the event drew 16,505 industry leaders from 65 countries.

Through its advocacy efforts, BIO’s Food and Agriculture Section supports a regulatory framework that facilitates and enables the development and commercialization of new biotechnology-derived plant products.

In this two part series, Scientific American’s Jeremy Abbate talks to editors Mike May and Yali Friedman about the Worldview Report and Scorecard, which will be released at the upcoming BIO International Convention in Boston at a Super Session on June 19.

In this two part series, Scientific American’s Jeremy Abbate talks to editors Mike May and Yali Friedman about the Worldview Report and Scorecard, which will be released at the upcoming BIO International Convention in Boston at a Super Session on June 19.

Phyllis discusses the importance of making connections in the industry to propel women into leadership roles, and plans for the upcoming BIO International Convention in Boston, Mass. On June 18-21.

BIO President and CEO Jim Greenwood talks with Arnold Thackray, President and CEO of the Life Sciences Foundation, about how the life sciences will shape the course of the 21st century.

Dr. Shawver discusses why this is an exciting time for the industry, and her experiences as a bench scientist turned CEO and founder of a patient advocacy group.

Bob Coughlin discusses the elements of supportive bioscience industry climates and looks ahead to the 2012 BIO International Convention.

Dr. Cohen discusses the plight of today’s emerging biotech companies, and how the federal government can best support innovation within the industry.

BIO President & CEO Jim Greenwood and Tom Watkins, President & CEO of Human Genome Sciences and Chair of BIO’s Board of Directors, recently hosted a media briefing to recap our advocacy accomplishments in 2011 and lay out BIO’s policy priorities for 2012.

Pavilions attract attendees and media alike, affording a space to tell your story within the context of a particular geographic region or specific focus area.

Congress has the opportunity to help speed lifesaving cures and treatments to patients by removing burdens to innovation in our industry.

Where can you network and partner with 15,000+ industry leaders from 65 countries across the globe?

There are many reasons to be excited about financing early stage biotech companies. The BIO Investor Forum will assemble the most promising among promising discovery stage companies. 

January 24 2013
To ensure transparency and communication between patients and their treatment teams, BIO believes that certain safeguards should guide substitution policies for interchangeable biologics under state law as well.
October 4 2010
BIO policy recommends that BIO members anticipate, consider and develop approaches to help manage and mitigate any potential significant, unintentional processing, product functional or compositional negative effects in crop use or processing streams.
Comments are regarding conservation and stewardship requirements, matching payments, establishment costs and annual payments, disclosure of competitively sensitive information, invasiveness determination and review, consistency with existing FSA programs, corporations and publicly traded company participation, eligible materials, and algae.
June 6 2012
The report will be released at a Super Session, titled "International Leaders Share Their Worldview: Scientific American's Regional Bio-Innovation Scorecard."
March 2 2012
The Biotechnology Industry Organization (BIO) announced today that it has integrated its alliance development activities into one department as a means of expanding engagement opportunities with external groups that share a commitment to unleashing biotechnology’s capability to benefit patients and consumers.
February 9 2012
BIO President and CEO Jim Greenwood issued the following statement regarding the newly released U.S. Food and Drug Administration (FDA) guidance for the review and approval of biosimilars.
October 13 2011
BIO President and CEO Jim Greenwood released the following statement on the Obama Administration's intent to create a National Bioeconomy Blueprint.
October 7 2011
In a case brought against USDA’s Animal and Plant Health Inspection Service (APHIS), the U.S. District Court for the Southern District of Florida has denied the plaintiff’s motion for summary judgment and granted the summary judgment motions for the government, ArborGen, and BIO.